Objective—To examine the biological behavior of ulnar osteosarcoma and evaluate predictors of survival time in dogs.
Design—Retrospective case series.
Animals—30 dogs with primary ulnar osteosarcoma.
Procedures—Medical records were reviewed. Variables recorded and examined to identify predictors of survival time were signalment, tumor location in the ulna, tumor length, serum alkaline phosphatase activity, surgery type, completeness of excision, tumor stage, tumor grade, histologic subtype, development of metastases, and use of chemotherapy.
Results—30 cases were identified from 9 institutions. Eleven dogs were treated with partial ulnar ostectomy and 14 with amputation; in 5 dogs, a resection was not performed. Twenty-two dogs received chemotherapy. Median disease-free interval and survival time were 437 and 463 days, respectively. Negative prognostic factors for survival time determined via univariate analyses were histologic subtype and development of lung metastases. Telangiectatic or telangiectatic-mixed subtype (n = 5) was the only negative prognostic factor identified via multivariate analysis (median survival time, 208 days). Dogs with telangiectatic subtype were 6.99 times as likely to die of the disease.
Conclusions and Clinical Relevance—The prognosis for ulnar osteosarcoma in this population was no worse and may have been better than the prognosis for dogs with osteosarcoma involving other appendicular sites. Partial ulnar ostectomy was associated with a low complication rate and good to excellent function and did not compromise survival time. Telangiectatic or telangiectatic-mixed histologic subtype was a negative prognostic factor for survival time. The efficacy of chemotherapy requires further evaluation.
Objective—To determine the prognostic factors for
survival and tumor recurrence in dogs with cutaneous
mast cell tumors (MCTs) in the perineal and inguinal
regions treated surgically with or without adjunctive
radiation therapy, chemotherapy, or both.
Procedure—Medical records of dogs with histologically
confirmed MCTs in the perineal region, inguinal
region, or both treated surgically with or without
adjunctive radiation therapy, chemotherapy, or both
Results—Mean tumor-free interval was 1,635 days
(median not reached), and 1- and 2-year tumor-free
rates were 79% and 71%, respectively. Median survival
time was 1,111 days (mean, 1,223 days), and 1-
and 2-year survival rates were 79% and 61%, respectively.
Factors that negatively influenced survival time
were age at diagnosis, tumor recurrence, and treatment
Conclusions and Clinical Relevance—Results indicated
that dogs with MCTs in the inguinal and perineal
regions, if appropriately treated, may have survival
times and tumor-free intervals similar to dogs
with MCTs in other locations. ( J Am Vet Med Assoc